Irish
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)

Study of Oral Anthocyanins on Insulin Resistance

Ní féidir ach le húsáideoirí cláraithe ailt a aistriú
Logáil Isteach / Cláraigh
Sábháiltear an nasc chuig an gearrthaisce
StádasCríochnaithe
Urraitheoirí
University of Aberdeen

Keywords

Coimriú

Dietary strategies for alleviating the metabolic complications such as diabetes associated with obesity are actively being pursued as alternatives to pharmaceutical interventions The genus Vaccinium (e.g. blueberry, blaeberry, cranberry) has been used traditionally as a source of folk remedies for established diabetic symptoms, primarily as leaf or stem infusions or decoctions. Berries from this family such as blaeberry (BL) and blueberry (BB) are enriched in anthocyanins, polyphenolics recognized for their ability to provide and activate cellular antioxidant protection, inhibit inflammatory gene expression, and consequently protect against oxidant-induced and inflammatory cell damage and cytotoxicity. The association of obesity with adipose tissue stress, macrophage recruitment, and inflammatory gene expression suggests that eating edible berries from this genus might provide an effective alternative or supplementary intervention to attenuate obesity- associated inflammation and the associated insulin resistance.
The aim of this study is to determine the effects of anthocyanin supplementation in the form of a concentrated blaeberry extract on insulin resistance and inflammation particularly in the adipose tissue following a three week supplementation period.

Dátaí

Fíoraithe Deireanach: 07/31/2019
Cuireadh isteach den chéad uair: 08/10/2010
Clárú Measta Curtha isteach: 08/10/2010
Arna chur suas ar dtús: 08/11/2010
Nuashonrú Deireanach Curtha isteach: 07/31/2019
Nuashonrú Deireanach Postáilte: 08/01/2019
Dáta Tosaigh an Staidéir Iarbhír: 05/31/2010
Dáta Críochnaithe Bunscoile Measta: 04/30/2019
Dáta Críochnaithe an Staid Mheasta: 04/30/2019

Coinníoll nó galar

Type 2 Diabetes

Idirghabháil / cóireáil

Dietary Supplement: Mirtoselect

Céim

-

Grúpaí Láimhe

LámhIdirghabháil / cóireáil
Active Comparator: Blaeberry concentrated caspule
30 obese male subjects (BMI > 30) with type 2 diabetes controlling their diabetes by diet alone or impaired glucose tolerance. Volunteers will be given a total daily dose of 1.4 grams of mirtoselect (a concentrated blaeberry extract) a day formulated in hard gelatin capsules (0.47 gram per capsule) administered thrice a day for 21 days. Mirtoselect provided by Indena S.p.A. (http://www.mirtoselect.info/)
Placebo Comparator: Placebo capsules containing lactose
30 obese male subjects (BMI > 30) with type 2 diabetes controlling their diabetes by diet alone or impaired glucose tolerance. Volunteers will be given a placebo consisting of lactose formulated in hard gelatin capsules administered thrice a day for 21 days.

Critéir Incháilitheachta

Aois Incháilithe le haghaidh Staidéir 40 Years Chun 40 Years
Gnéas Incháilithe le haghaidh StaidéirMale
Glacann Oibrithe Deonacha SláintiúlaSea
Critéir

Inclusion Criteria:

- Obese male subjects (BMI > 30)

- Aged > 40 and < 70 years of age

- Type 2 diabetes; subjects controlling their diabetes by diet alone or with impaired glucose tolerance

- All the obese subjects will have a waist circumference over 40 inches

- All subjects must live the Aberdeenshire area of Scotland

Exclusion Criteria:

Medical exclusion criteria:

- Chronic illness, including:

- thromboembolic or coagulation disease,

- unregulated thyroid disease,

- kidney disease,

- hepatic disease,

- severe gastrointestinal disorders,

- pulmonary disease (e.g. chronic bronchitis, COPD),

- Alcohol or any other substance abuse,

- Eating disorders,

- Psychiatric disorders (including severe depression, lithium treatment, schizophrenia, severe behavioural disorders),

- Skin conditions on the abdomen,

- Allergy to skin dressings,

Medication exclusion criteria:

- Oral steroids,

- Tricyclic antidepressants, neuroleptics,

- Anticoagulants,

- Digoxin and antiarrhythmics,

- Chronic use of antiinflammatories (e.g. high doses of aspirin, ibuprofen),

- Insulin, Sulphonylureas, Thiazolidinediones (glitazones), metformin

Toradh

Bearta Toraidh Príomhúla

1. Oral Glucose Tolerance Test [Day 0 and 21 days post intervention]

Change in Oral Glucose Tolerance following intervention

Bearta Torthaí Tánaisteacha

1. Fasting blood glucose/insulin [Day 0, 7, 14, and 21 days post intervention]

Change in fasting blood glucose/insulin in response to intervention

Bí ar ár
leathanach facebook

An bunachar luibheanna míochaine is iomláine le tacaíocht ón eolaíocht

  • Oibreacha i 55 teanga
  • Leigheasanna luibhe le tacaíocht ón eolaíocht
  • Aitheantas luibheanna de réir íomhá
  • Léarscáil GPS idirghníomhach - clibeáil luibheanna ar an láthair (ag teacht go luath)
  • Léigh foilseacháin eolaíochta a bhaineann le do chuardach
  • Cuardaigh luibheanna míochaine de réir a n-éifeachtaí
  • Eagraigh do chuid spéiseanna agus fanacht suas chun dáta leis an taighde nuachta, trialacha cliniciúla agus paitinní

Clóscríobh symptom nó galar agus léigh faoi luibheanna a d’fhéadfadh cabhrú, luibh a chlóscríobh agus galair agus comharthaí a úsáidtear ina choinne a fheiceáil.
* Tá an fhaisnéis uile bunaithe ar thaighde eolaíoch foilsithe

Google Play badgeApp Store badge